Get the Stockscreener App
1.49
1.32%
-0.02
After Hours:
1.50
0.01
+0.67%
Aprea Therapeutics Inc stock is traded at $1.49, with a volume of 131.23K.
It is down -1.32% in the last 24 hours and down -1.32% over the past month.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
See More
Previous Close:
$1.51
Open:
$1.51
24h Volume:
131.23K
Relative Volume:
2.65
Market Cap:
$8.68M
Revenue:
-
Net Income/Loss:
$-14.29M
P/E Ratio:
-0.3734
EPS:
-3.99
Net Cash Flow:
$-12.27M
1W Performance:
+4.05%
1M Performance:
-1.32%
6M Performance:
-5.70%
1Y Performance:
-51.15%
1-Day Range:
$1.48
$1.57
1-Week Range:
$1.395
$1.57
52-Week Range:
$1.37
$5.01
Aprea Therapeutics Inc Stock (APRE) Company Profile
Name
Aprea Therapeutics Inc
Sector
Industry
Phone
215-948-4119
Address
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
1.49 | 8.80M | 0 | -14.29M | -12.27M | -3.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.90 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
470.27 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.42 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
815.61 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
316.15 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Jun-22-20 | Initiated | H.C. Wainwright | Neutral |
| Apr-21-20 | Initiated | Robert W. Baird | Outperform |
| Oct-28-19 | Initiated | JP Morgan | Neutral |
| Oct-28-19 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-28-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Aprea Therapeutics Inc Stock (APRE) Latest News
Visualizing Aprea Therapeutics Inc. stock with heatmaps2025 Risk Factors & Consistent Profit Trading Strategies - newser.com
Risk vs reward if holding onto Aprea Therapeutics Inc.Earnings Recap Summary & Community Supported Trade Ideas - newser.com
Is Aprea Therapeutics Inc. stock poised for growthEarnings Beat & Growth Focused Stock Reports - newser.com
Aprea sets 1,100 mg dose for ATR inhibitor, shifts focus to combinations - Investing.com Canada
Aprea sets 1,100 mg dose for ATR inhibitor, shifts focus to combinations By Investing.com - Investing.com South Africa
Aprea Therapeutics Shifts Focus to Combination Therapies - TipRanks
Aprea Therapeutics Establishes Recommended Phase 2 Dose for ATRN-119 - TradingView
Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies - The Manila Times
1,100 mg RP2D: Aprea Therapeutics shifts ATRN-119 to combination focus, pauses monotherapy enrollment - Stock Titan
Aprea Therapeutics Announces Presentations at - GlobeNewswire
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics - Stock Titan
Sentiment analysis tools applied to Aprea Therapeutics Inc.Market Activity Summary & Fast Exit/Entry Strategy Plans - newser.com
Developing predictive dashboards with Aprea Therapeutics Inc. dataInsider Selling & AI Powered Market Trend Analysis - newser.com
How to recover losses in Aprea Therapeutics Inc. stock2025 Technical Overview & Technical Buy Zone Confirmation - newser.com
Using economic indicators to assess Aprea Therapeutics Inc. potential2025 Breakouts & Breakdowns & Safe Entry Zone Tips - newser.com
Should you wait for a breakout in Aprea Therapeutics Inc.July 2025 Selloffs & Smart Investment Allocation Insights - newser.com
Aprea Therapeutics (NASDAQ:APRE) Trading Down 3% – Here’s What Happened - Defense World
Historical volatility pattern of Aprea Therapeutics Inc. visualizedPortfolio Growth Summary & Daily Growth Stock Tips - newser.com
Can Aprea Therapeutics Inc. rally from current levelsWeekly Trend Report & Long-Term Growth Stock Strategies - newser.com
How sentiment analysis helps forecast Aprea Therapeutics Inc.Market Rally & Free Safe Capital Growth Stock Tips - newser.com
Published on: 2025-10-03 04:24:53 - newser.com
How to integrate Aprea Therapeutics Inc. into portfolio analysis toolsJuly 2025 Selloffs & Precise Swing Trade Alerts - newser.com
Reversal indicators forming on Aprea Therapeutics Inc. stockJobs Report & Verified Chart Pattern Signals - newser.com
What analysts say about Aprea Therapeutics Inc stockPrice Support Zones & Low Cost Trading Plans - earlytimes.in
Published on: 2025-09-30 01:07:35 - newser.com
Published on: 2025-09-29 04:10:00 - newser.com
What drives Aprea Therapeutics Inc stock priceTrade Execution Strategies & Big Returns Small Capital - earlytimes.in
Is Aprea Therapeutics Inc a good long term investmentMACD Trading Signals & Rapid Capital Trading Tips - Early Times
Published on: 2025-09-27 17:04:35 - newser.com
Live market analysis of Aprea Therapeutics Inc.2025 Sector Review & Stock Portfolio Risk Control - newser.com
Using portfolio simulators with Aprea Therapeutics Inc. includedJuly 2025 Trends & Weekly Market Pulse Alerts - newser.com
Aprea Therapeutics Inc Stock (APRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.09%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):